FDA approves Gomekli as first neurofibromatosis drug for adults
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat neurofibromatosis type 1 (NF1), a type of rare genetic disorder. Both adult and paediatric patients with NF1 who have symptomatic plexiform neurofibromas (PN) that cannot be surgically removed will be eligible for the treatment.
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...
The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback